PDL BioPharma Company Profile (NASDAQ:PDLI)

About PDL BioPharma

PDL BioPharma logoPDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PDLI
  • CUSIP: 69329Y10
Key Metrics:
  • Previous Close: $2.28
  • 50 Day Moving Average: $2.27
  • 200 Day Moving Average: $2.73
  • 52-Week Range: $1.93 - $3.84
  • Trailing P/E Ratio: 2.16
  • Foreward P/E Ratio: 11.40
  • P/E Growth: 0.30
  • Market Cap: $377.43M
  • Outstanding Shares: 165,540,000
  • Beta: 0.52
Profitability:
  • Net Margins: 49.04%
  • Return on Equity: 29.87%
  • Return on Assets: 20.18%
Debt:
  • Debt-to-Equity Ratio: 0.31%
  • Current Ratio: 2.92%
  • Quick Ratio: 2.91%
Additional Links:
Companies Related to PDL BioPharma:

Analyst Ratings

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $3.83 (68.13% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetDetails
12/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$4.00View Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
2/23/2016Royal Bank Of CanadaLower Price TargetSector Perform$5.00 -> $4.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for PDL BioPharma (NASDAQ:PDLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
2/23/2017Q4 2016$0.09N/AView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)
Current Year EPS Consensus Estimate: $0.54 EPS
Next Year EPS Consensus Estimate: $0.20 EPS

Dividends

Current Dividend Information for PDL BioPharma (NASDAQ:PDLI)
Annual Dividend:$0.10
Dividend Yield:4.39%
Payout Ratio:9.43% (Based on Trailing 12 Months of Earnings)
18.52% (Based on Current Year Consensus EPS Estimate)
50.00% (Based on Next Year Consensus EPS Estimate)

Dividend History for PDL BioPharma (NASDAQ:PDLI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for PDL BioPharma (NASDAQ:PDLI)
Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 78.88%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
DateHeadline
News IconABR Of PDL BioPharma, Inc. (NASDAQ:PDLI) Stock At 2 - Stock Observer (NASDAQ:PDLI)
www.thestockobserver.com - February 23 at 12:17 AM
finance.yahoo.com logoPDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017 (NASDAQ:PDLI)
finance.yahoo.com - February 22 at 9:14 AM
marketexclusive.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Regulation FD Disclosure (NASDAQ:PDLI)
marketexclusive.com - February 21 at 5:43 PM
News IconChart Update on Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) - BVN (NASDAQ:PDLI)
bvnewsjournal.com - February 18 at 11:40 AM
News IconDividend Growth of PDL BioPharma, Inc.(PDLI) - Highland Mirror (NASDAQ:PDLI)
www.highlandmirror.com - February 18 at 11:40 AM
finance.yahoo.com logoPDL BioPharma to Present at the 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:PDLI)
finance.yahoo.com - February 17 at 8:10 AM
marketnewsvideo.com logoShort Interest Increases 29.7% For PDLI (NASDAQ:PDLI)
www.marketnewsvideo.com - February 10 at 8:07 PM
News IconStock Check: Viewing Levels for PDL BioPharma Inc. (PDLI) - Piedmont Register (NASDAQ:PDLI)
piedmontregister.com - February 8 at 8:07 PM
News IconAnalyst Advice And Earnings Insight: Masco Corporation (NYSE:MAS), PDL BioPharma, Inc. (NASDAQ:PDLI) - Post Analyst (NASDAQ:PDLI)
postanalyst.com - February 7 at 8:18 PM
finance.yahoo.com logoPDL BioPharma Inc. Review of 3Q 2016 Results and Forward Outlook (NASDAQ:PDLI)
finance.yahoo.com - January 31 at 8:11 PM
realistinvestor.com logoDeferred Tax Assets Of PDL BioPharma, Inc. (NASDAQ:PDLI) At ... - RealistInvestor.com (NASDAQ:PDLI)
www.realistinvestor.com - January 31 at 5:52 AM
News IconBargain Hunters Should Take a Look at PDL BioPharma, Inc. (NASDAQ:PDLI) - Prospect Journal (NASDAQ:PDLI)
prospectjournal.com - January 31 at 5:52 AM
News IconWhat's Ahead For This Dividend Darling: PDL BioPharma, Inc. (NASDAQ:PDLI) - Aiken Advocate (NASDAQ:PDLI)
aikenadvocate.com - January 31 at 5:52 AM
News IconInvestor Watch: Volatility Review for PDL BioPharma, Inc. (NASDAQ:PDLI) - Gilbert Daily (NASDAQ:PDLI)
gilbertdaily.com - January 29 at 7:37 PM
News IconLENSAR Launches Streamline III to Assist Cataract Surgeons in Managing and Improving Astigmatism Treatment for Optimal Visual Outcomes (NASDAQ:PDLI)
www.cbs58.com - January 27 at 5:38 AM
News IconNarrowing in on Chart Levels for PDL BioPharma Inc. (PDLI) - Sherwood Daily (NASDAQ:PDLI)
sherwooddaily.com - January 27 at 12:38 AM
finance.yahoo.com logoLENSAR® Launches Streamline™ III to Assist Cataract Surgeons in Managing and Improving Astigmatism Treatment for Optimal Visual Outcomes (NASDAQ:PDLI)
finance.yahoo.com - January 27 at 12:38 AM
News IconTicker Watch: Technical Views on Shares of PDL BioPharma Inc. (PDLI) - Sherwood Daily (NASDAQ:PDLI)
sherwooddaily.com - January 25 at 12:55 AM
istreetwire.com logoStocks Buzz: Fairmount Santrol Holdings Inc. (FMSA), PDL BioPharma, Inc. (PDLI), L Brands, Inc. (LB) - iStreetWire (NASDAQ:PDLI)
istreetwire.com - January 25 at 12:55 AM
News IconQuarterly Financial Review of PDL BioPharma, Inc. (NASDAQ:PDLI) - The Newburgh Press (NASDAQ:PDLI)
newburghpress.com - January 25 at 12:55 AM
realistinvestor.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Deferred Tax Assets At $0.981 Millions - RealistInvestor.com (NASDAQ:PDLI)
www.realistinvestor.com - January 24 at 8:45 AM
News IconThe PDL BioPharma Inc. (PDLI) Coverage Initiated at Piper Jaffray Cos (NASDAQ:PDLI)
perspectivabetica.com - January 22 at 1:21 AM
News IconTrading Indicator Check on PDL BioPharma Inc. (PDLI) - Sherwood Daily (NASDAQ:PDLI)
sherwooddaily.com - January 21 at 1:00 AM
capitalcube.com logoETFs with exposure to PDL BioPharma, Inc. : January 20, 2017 (NASDAQ:PDLI)
www.capitalcube.com - January 20 at 7:59 PM
finance.yahoo.com logoCan PDL BioPharma Be a Top Choice for Value Investors? (NASDAQ:PDLI)
finance.yahoo.com - January 19 at 11:53 PM
News IconPlacing the Bulls-Eye Focus on PDL BioPharma, Inc. (NASDAQ:PDLI) - Prospect Journal (NASDAQ:PDLI)
prospectjournal.com - January 18 at 8:39 AM
News IconPDL BioPharma, Inc. PDLI Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:PDLI)
www.bioportfolio.com - January 14 at 5:48 AM
istreetwire.com logoThree Movers to Watch for: News Corporation (NWSA), PDL BioPharma, Inc. (PDLI), Amyris, Inc. (AMRS) - iStreetWire (NASDAQ:PDLI)
istreetwire.com - January 13 at 8:04 AM
News IconStock ABR PDL BioPharma, Inc. (NASDAQ:PDLI) At 2 - Stock Observer (NASDAQ:PDLI)
www.thestockobserver.com - January 12 at 5:51 AM
News IconPDL BioPharma, Inc. (NASDAQ:PDLI) Closed the Last Trading Session with increase of 3.08% - The Newburgh Press (NASDAQ:PDLI)
newburghpress.com - January 12 at 5:51 AM
marketexclusive.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:PDLI)
marketexclusive.com - January 10 at 8:00 AM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:PDLI)
biz.yahoo.com - January 9 at 7:49 PM
News IconPDL BioPharma Inc PDLI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PDLI)
www.bioportfolio.com - January 8 at 4:26 AM
News IconCheap Stock Alert & Update on PDL BioPharma, Inc. (NASDAQ:PDLI) - Prospect Journal (NASDAQ:PDLI)
prospectjournal.com - December 30 at 7:31 PM
News IconStreetwise Investors Taking Note of PDL BioPharma, Inc. (NASDAQ:PDLI) - Prospect Journal (NASDAQ:PDLI)
prospectjournal.com - December 30 at 12:06 AM
News IconKunming high-speed rail in full operation (NASDAQ:PDLI)
vouxmagazine.com - December 29 at 7:05 PM
businesswire.com logoLENSAR® Strategic Restructure in Partnership with PDL BioPharma ... - Business Wire (press release) (NASDAQ:PDLI)
www.businesswire.com - December 21 at 9:42 AM
marketexclusive.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Entry into a ... - Market Exclusive (NASDAQ:PDLI)
marketexclusive.com - December 21 at 9:42 AM
News IconInvestor Watch: Looking at Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) - Liberty News (NASDAQ:PDLI)
libertynewsrecord.com - December 20 at 11:40 PM
streetinsider.com logoLENSAR Files Chapter 11 Bankruptcy with Support of Senior Secured Lender PDL BioPharma (PDLI) (NASDAQ:PDLI)
www.streetinsider.com - December 20 at 6:39 PM
News IconLensAR Files for Chapter 11 With Support From PDL BioPharma (NASDAQ:PDLI)
www.biospace.com - December 20 at 6:39 PM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events (NASDAQ:PDLI)
biz.yahoo.com - December 20 at 6:39 PM
streetinsider.com logoLENSAR Files Chapter 11 Bankruptcy with Support of Senior Secured Lender PDL BioPharma (PDLI) - StreetInsider.com (NASDAQ:PDLI)
www.streetinsider.com - December 20 at 1:36 PM
finance.yahoo.com logoLENSAR® Strategic Restructure in Partnership with PDL BioPharma, Inc. (NASDAQ:PDLI)
finance.yahoo.com - December 20 at 1:36 PM
capitalcube.com logoETFs with exposure to PDL BioPharma, Inc. : December 19, 2016 (NASDAQ:PDLI)
www.capitalcube.com - December 20 at 1:36 PM
wsj.com logo[$$] Medical-Device Company Enters Chapter 11 (NASDAQ:PDLI)
www.wsj.com - December 20 at 1:36 PM
News IconCompany Watch for PDL BioPharma, Inc. (NASDAQ:PDLI) - Liberty News (NASDAQ:PDLI)
libertynewsrecord.com - December 19 at 8:42 AM
News IconCompany Focus on Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) - Business Daily Leader (NASDAQ:PDLI)
businessdailyleader.com - December 18 at 6:27 AM
News IconMarket Survey: Checking on Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) - Liberty News (NASDAQ:PDLI)
libertynewsrecord.com - December 17 at 12:56 AM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:PDLI)
biz.yahoo.com - December 16 at 7:54 PM

Social

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How often does PDL BioPharma pay dividends? What is the dividend yield for PDL BioPharma?

PDL BioPharma announced a quarterly dividend on Wednesday, May 4th. Shareholders of record on Monday, June 6th will be given a dividend of $0.05 per share on Monday, June 13th. This represents a $0.20 dividend on an annualized basis and a yield of 8.77%. The ex-dividend date of this dividend is Thursday, June 2nd.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?

3 brokers have issued 12 month target prices for PDL BioPharma's stock. Their forecasts range from $3.50 to $4.00. On average, they anticipate PDL BioPharma's stock price to reach $3.83 in the next year.

When will PDL BioPharma announce their earnings?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

  • According to Zacks Investment Research, "PDL BioPharma is focused on acquiring and managing income-generating assets. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. The latest example is that of privately held specialty pharmaceutical company, Noden Pharma. The ARIAD deal is another positive. We note that the company derives revenues primarily from royalties, which is not a risk-free strategy. Uncertainty related to the future source of revenues is another cause of concern. The company’s top line has declined materially after it stopped receiving payments from certain Queen et al. patent licenses. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year. Estimates are down ahead the company’s Q4 release." (1/17/2017)

  • Cowen and Company analysts commented, "PDL reported Q4 revenue of $178.1MM ahead of consensus of $167.9MME and GAAP." (2/23/2016)

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.78%), Dimensional Fund Advisors LP (2.59%), State Street Corp (2.58%), AQR Capital Management LLC (2.25%), Russell Investments Group Ltd. (1.17%) and GSA Capital Partners LLP (0.96%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Guggenheim Capital LLC, Bowling Portfolio Management LLC, Zebra Capital Management LLC and Barrow Hanley Mewhinney & Strauss LLC.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, AQR Capital Management LLC, Dimensional Fund Advisors LP, Allianz Asset Management AG, State Street Corp, Cigna Investments Inc. New and Federated Investors Inc. PA. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PDL BioPharma stock cost?

One share of PDL BioPharma stock can currently be purchased for approximately $2.28.

PDL BioPharma (NASDAQ:PDLI) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for PDL BioPharma (NASDAQ:PDLI)

Earnings History Chart

Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)

Dividend History Chart

Dividend Payments by Quarter for PDL BioPharma (NASDAQ:PDLI)

Last Updated on 2/23/2017 by MarketBeat.com Staff